Mutations that cause spinal muscular atrophy (SMA) may lead to abnormalities in the development of cells in the spinal cord, a study found.

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies ...

Biogen’s salanersen is now heading into three Phase III trials in SMA.

The Electric Wheelchair Market has witnessed significant growth in recent years due to the rising demand for advanced mobility solutions for individuals with disabilities and the aging population.

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene ...

MDA 2026 keynote speaker John Crowley discussed with MD News Today the progress made in neuromuscular disease and the future challenges.

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

Biogen has launched a trio of Phase 3 trials to test salanersen, a new SMA treatment that aims to be a more convenient ...

Genethon, a pioneer and leader in gene therapy for rare diseases, unveiled results at the MDA Conference in Orlando confirming the long-term efficacy of its GNT0004 gene therapy in Duchenne muscular ...

US biotech major Biogen has presented additional results from the Phase Ib study of salanersen, an investigational novel ...

NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...